F2G
PITCH
F2G believes that its novel agent, olorofim, and subsequent agents, will address some of the many challenges which face the treating physician and the patient with invasive fungal infections.
LATEST INVESTMENT
#HealthTech
08.2020
F2G
£46.7M
Cowen Healthcare Investments, Novo Holdings, Morningside Ventures, Brace Pharma Capital, Advent Life Sciences